Can Intravenous Vitamin C Improve Skin Hyperpigmentation in Long-Term Hemodialysis Patients?

The recruitment status of this study is unknown because the information has not been verified recently.
Verified May 2005 by National Taiwan University Hospital.
Recruitment status was  Not yet recruiting
Sponsor:
Information provided by:
National Taiwan University Hospital
ClinicalTrials.gov Identifier:
NCT00172302
First received: September 12, 2005
Last updated: NA
Last verified: May 2005
History: No changes posted
  Purpose

Intravenous vitamin C may improve skin hyperpigmentation in chronic hemodialysis patients


Condition Intervention
Kidney Failure, Chronic
Drug: vitamin C, intravenous injection

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: Can Intravenous Vitamin C Improve Skin Hyperpigmentation in Long-Term Hemodialysis Patients?

Resource links provided by NLM:


Further study details as provided by National Taiwan University Hospital:

Primary Outcome Measures:
  • Skin pigmentation extent

Secondary Outcome Measures:
  • blood anti-oxidant level

Estimated Enrollment: 40
Study Start Date: November 2005
Detailed Description:

Melanogenesis is caused by enzymatic conversion of tyrosine to melanin pigments.Ascorbic acid has the ability to inhibit peroxidase and may thus inhibit melanin synthesis.

  Eligibility

Ages Eligible for Study:   20 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • chronic hemodialysis patients

Exclusion Criteria:

  • allergic to vitamin C, using steroid, etc
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00172302

Locations
Taiwan
National Taiwan University Hospital Not yet recruiting
Taipei, Taiwan, 100
Contact: Tze-Wah Kao, MD    886-2-2356-2000    twkao@ha.mc.ntu.edu.tw   
Principal Investigator: Tze-Wah Kao, MD         
Sponsors and Collaborators
National Taiwan University Hospital
Investigators
Principal Investigator: Kao Tze-Wah, MD National Taiwan University Hospital
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00172302     History of Changes
Other Study ID Numbers: 930105
Study First Received: September 12, 2005
Last Updated: September 12, 2005
Health Authority: Taiwan: Department of Health

Additional relevant MeSH terms:
Kidney Failure, Chronic
Renal Insufficiency
Hyperpigmentation
Renal Insufficiency, Chronic
Kidney Diseases
Urologic Diseases
Pigmentation Disorders
Skin Diseases
Ascorbic Acid
Vitamins
Antioxidants
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Protective Agents
Physiological Effects of Drugs
Micronutrients
Growth Substances

ClinicalTrials.gov processed this record on July 22, 2014